Cyclopharm Ltd (ASX: CYC) Share Price and News

Mr Heaney was appointed to the Cyclopharm Board on 20 November 2006 and is currently the Chairman of Cyclopharm and Chairman of the Remuneration and Board Nomination Committees. He was formerly Chairman of the Audit and Risk Committee until 28 February 2019. Mr Heaney was re appointed as acting Chairman of the Audit and Risk Committee effective 1 December 2021 until 18 February 2024. Mr Heaney has also served as a Non Executive Director of a number of ASX listed and non listed companies. Mr Heaney has more than 40 years experience in all aspects of wholesale banking and finance, gained in general management roles with National Australia Bank Limited and subsidiary companies in both Australia and the US.

Ms Angus was appointed to the Board on 10 August 2021. She is a member of the Audit and Risk Committee, Remuneration Committee and Board Nomination Committee. Ms Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. She has long been involved in path to market asset development and commercialisation in these industries, notably including the clinical validation of therapeutics to create asset valuation uplift. Ms Angus has wide expertise in corporate strategy and innovative product development together with governance and compliance in listed capital markets.

Mr McBrayer has been a member of the Board since 3 June 2008 at which time he accepted the role of Managing Director. Mr McBrayer serves as a member of the Board Nominations Committee. Mr McBrayer has more than 30 years experience in nuclear medicine and is a trained Nuclear Pharmacist. Mr McBrayer held the role of Managing Director at Lipa Pharmaceuticals, Australia's largest contract manufacturer of over the counter products and senior management positions with Brambles Cleanaway business and Syncor, the world's largest radioactive diagnostic and therapeutic pharmaceutical provider.

Mr Barrow was appointed to the Board on 1 September 2022. He is a member of the Audit and Risk Committee, Remuneration Committee and Board Nomination Committee. Mr Barrow holds a Master of Science (with 1st Class Honours) from Waikato University, New Zealand. He obtained an MBA from the Macquarie Graduate School of Management, Sydney, Australia and is a graduate of the Australian Institute of Company Directors and an Adjunct Fellow at Macquarie University. He brings to the Cyclopharm board more than 20 years of experience in the healthcare industry, which includes numerous governance and senior executive roles.

Dr King is Professor of Respiratory Medicine at the Northern and Central Clinical Schools of the University of Sydney. He is also the Staff Specialist in the Department of Respiratory Medicine at Royal North Shore Hospital, where he directs the asthma service and is the Medical Director of the Respiratory Investigation Unit, and the Research Leader of the Airway Physiology and Imaging Group at the Woolcock Institute of Medical Research. In addition, Dr. King supervises PhD and other postgraduate students at the University of Sydney.

Mr Wigglesworth brings with him 37 years of professional experience, including nearly 25 years as a Partner at KPMG. His background as a Chartered Accountant and Company Director, coupled with his industry experience. Mr Wigglesworths career include a company director having held several previous Board positions over the past decade including Atlas Arteria Limited (ASX:ALX) and also in public sector health entities, While at KPMG John advised and supported many Australian and international multinational companies during periods of international growth., Held various KPMG leadership positions including serving as a member of the Audit Leadership Group and National leader of KPMG Audits Retention & Conversion function, managing proposals, client relationship management, and global management groups/committees, Expertise in ASX listing readiness, IPOs, and business transition, working closely with companies navigating the challenges of transitioning to a listed entity, Financial reporting and market communications, on ASX and regulatory reporting along with financial reporting matters. He has experience in risk management, including Cyber, and serving as Chairman of the Audit & Risk Committee at both Atlas Arteria Limited and Macquarie University.